Nodular Lymphocyte Predominant Hodgkin Lymphoma, Lymph Nodes of Multiple Sites (C81.08)

Name of the Condition

• Common Name: Nodular Lymphocyte Predominant Hodgkin Lymphoma, Lymph Nodes of Multiple Sites
• Medical Terms: NLP Hodgkin Lymphoma, Lymphocyte-Predominant Hodgkin Lymphoma

Summary

Nodular lymphocyte predominant Hodgkin lymphoma (NLP Hodgkin lymphoma) is a rare subtype of Hodgkin lymphoma that originates in the lymphatic system. It is characterized by the presence of large, abnormal cells known as lymphocyte-predominant (LP) cells, which are distinct from the Reed-Sternberg cells seen in other Hodgkin lymphoma subtypes. The disease typically involves lymph nodes and may spread to other lymphoid tissues or organs. NLP Hodgkin lymphoma tends to have a more indolent course compared to other subtypes, with a higher likelihood of late relapses.

Causes

The exact cause of NLP Hodgkin lymphoma is not fully understood, but it is thought to result from a combination of genetic mutations and environmental factors. Unlike other Hodgkin lymphoma subtypes, Epstein-Barr virus (EBV) is rarely associated with NLP Hodgkin lymphoma. Research suggests that alterations in the B-cell receptor signaling pathway and other genetic abnormalities may play a role in its development.

Risk Factors

• Age: Most commonly diagnosed in adults, with a peak incidence in the 30-50 age range.
• Gender: Slightly more prevalent in males.
• Family history: A small increased risk may be associated with a family history of lymphoma.
• Immune system: Individuals with weakened immune systems may have a higher risk.

Symptoms

• Painless swelling of lymph nodes, often in the neck, armpit, or groin.
• Fatigue or weakness.
• Unexplained weight loss.
• Fever or night sweats.
• Loss of appetite.
• Itching (pruritus).

Diagnosis

Diagnosis typically involves a combination of physical examination, imaging studies (e.g., CT scans, PET scans), and biopsy of affected lymph nodes. The biopsy is examined under a microscope to identify the characteristic LP cells. Additional tests, such as blood work and bone marrow biopsy, may be performed to assess the extent of the disease and rule out other conditions.

Treatment Options

Treatment depends on the stage and extent of the disease. Options may include:

• Radiation therapy: Targeted to affected lymph nodes.
• Immunotherapy: Such as rituximab, which targets specific proteins on cancer cells.
• Chemotherapy: Used in more advanced cases or when the disease has spread.
• Watchful waiting: For early-stage, slow-growing cases.

Prognosis and Follow-Up

NLP Hodgkin lymphoma generally has a good prognosis, especially when diagnosed at an early stage. However, late relapses can occur, requiring long-term monitoring. Follow-up care typically includes regular physical exams, imaging, and blood tests to detect recurrence or complications.

Complications

• Recurrence of the disease, sometimes years after initial treatment.
• Secondary cancers, such as non-Hodgkin lymphoma or leukemia, due to treatment.
• Infection risk from weakened immune system.
• Fatigue and other long-term side effects from treatment.

Lifestyle & Prevention

• Maintain a healthy lifestyle with balanced nutrition and regular exercise.
• Avoid known carcinogens, such as tobacco and excessive alcohol.
• Stay up-to-date with vaccinations to reduce infection risk.
• Manage stress and prioritize rest to support immune function.

When to Seek Professional Help

Seek medical attention if you experience persistent, painless lymph node swelling, unexplained weight loss, fever, or night sweats. Early evaluation is important for accurate diagnosis and timely treatment.

Tips for Medical Coders

When coding for C81.08, ensure the documentation specifies involvement of lymph nodes at multiple sites. Verify that the diagnosis aligns with the clinical criteria for nodular lymphocyte predominant Hodgkin lymphoma and that the site is clearly documented as "multiple" rather than a single or unspecified site. Accurate site specification is critical for correct code assignment.